Compare GEOS & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEOS | MDWD |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.9M | 224.6M |
| IPO Year | 1997 | 2013 |
| Metric | GEOS | MDWD |
|---|---|---|
| Price | $12.07 | $16.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 186.8K | 73.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,803,000.00 | N/A |
| Revenue This Year | N/A | $57.63 |
| Revenue Next Year | N/A | $26.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.52 | $14.14 |
| 52 Week High | $29.89 | $22.51 |
| Indicator | GEOS | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 40.73 |
| Support Level | $10.50 | N/A |
| Resistance Level | $16.34 | $18.58 |
| Average True Range (ATR) | 0.79 | 0.60 |
| MACD | 0.62 | -0.05 |
| Stochastic Oscillator | 89.35 | 8.65 |
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.